Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ALX Oncology Holdings Inc. filings document a clinical-stage biotechnology issuer focused on cancer therapeutics and its Nasdaq-listed common stock. Recent 8-K reports furnish quarterly and annual financial results, corporate updates, clinical data releases for evorpacept and ALX2004, preliminary cash and investment information, and capital-structure disclosures tied to common stock and pre-funded warrant financing.
Proxy and governance filings describe board matters, executive compensation, equity awards, and shareholder voting items. Other material-event reports cover officer appointments, employment and compensatory arrangements, and amendments to the 2025 Inducement Equity Incentive Plan under Nasdaq inducement award rules.
Redmile Group, LLC and related parties report an 8.5% economic interest in ALX Oncology (ALXO). The filing discloses beneficial ownership of 4,641,455 shares in total, composed of 3,391,455 shares of common stock and 1,250,000 shares issuable upon exercise of warrants. Redmile Biopharma Investments III, L.P. holds 3,675,481 shares (6.7%). Percentages are calculated using 53,444,020 shares outstanding as of May 1, 2025 plus the 1,250,000 warrant shares. The reporters state shared voting and dispositive power and disclaim sole ownership beyond pecuniary interest.
Curran Daniel J., a director of ALX Oncology Holdings Inc. (ALXO), acquired a stock option grant for 40,400 shares on 08/12/2025. The option carries an exercise price of $0.615 and an expiration date of 08/11/2035. According to the filing, the shares subject to the option vest in 36 equal monthly installments beginning on September 12, 2025.
The Form 4 was filed by one reporting person and signed under power of attorney on 08/13/2025. The transaction is recorded as an acquisition of a derivative security whose underlying title is common stock; the ownership is reported as direct.
ALX Oncology Holdings Inc. (ALXO) filed an initial Form 3 on behalf of Daniel J. Curran, reporting his relationship to the issuer as a Director. The filing states the event date as 08/12/2025 and includes a signed submission dated 08/13/2025 executed by Shelly Pinto under power of attorney. The document explicitly states no securities are beneficially owned by the reporting person.
ALX Oncology Holdings reported unaudited Q2 2025 results showing total assets of $95.3 million and total stockholders' equity of $64.4 million. Cash and cash equivalents were $19.3 million with short-term investments of $60.0 million and long-term investments of $4.2 million, for a total fair-value investment balance of $81.8 million. The company recorded a net loss of $25.9 million for the three months ended June 30, 2025 and $56.7 million for the six months, and had an accumulated deficit of $677.8 million.
Operationally, R&D expense was $18.0 million in the quarter (down 48% year-over-year), driven by lower clinical and preclinical spend and reduced stock-based compensation. The company recognized a $3.2 million impairment charge related to a to-be-sublet Palo Alto property. Clinical highlights include ASPEN-06 Phase 2 signals: ITT ORR of 41.3% versus 26.6% TRP control and stronger benefit in CD47-high patients (e.g., ORR 65% in confirmed HER2+/CD47-high subgroup). The IND for ALX2004 was cleared in April 2025. The company received a Nasdaq minimum bid price notice on April 23, 2025 with a compliance period through October 20, 2025, and states existing capital resources are sufficient for at least the next 12 months.
ALX Oncology disclosed that it furnished a press release reporting financial results for the second quarter and full year ended June 30, 2025. The filing itself does not include the financial detail but references Exhibit 99.1 for the full release.
The company also expanded its board from six to seven members by appointing Daniel Curran, M.D. as a Class III director. Dr. Curran brings over 25 years of pharmaceutical experience, including recent roles as CEO of Timberlyne Therapeutics and prior senior leadership at Takeda. He will join the Corporate Governance and Nominating Committee and is designated as independent under applicable Nasdaq and SEC standards.
Under the outside director compensation policy Dr. Curran will receive an initial option award to purchase 40,400 shares that vests monthly over 36 months and will be eligible for annual cash and equity awards; an indemnification agreement was also executed. The filing lists updated board committee memberships.